Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2. ROC curves for different group comparisons

Published byMichelle Dumont Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 2. ROC curves for different group comparisons"— Presentation transcript:

1 Figure 2. ROC curves for different group comparisons
ROC curves for different group comparisons A) ROC curve for healthy controls vs. MS patients: Blue: ROC curve for best single miRNA, miR.320a AUC = Red: ROC curve for combination of six miRNAs (hsa.miR.320a + hsa.miR.486.5p + hsa.miR.320b + hsa.miR.25.3p + hsa.let.7c.5p + hsa.miR.140.3p), AUC = (B) ROC curve for patients with RRMS vs patients with PMS. Blue: ROC curve for hsa.miR.27a.3p. AUC = (C) ROC curve for patients with RRMS vs patients with SPMS. Blue: ROC curve for hsa.miR.27a.3p. AUC = (D) Scatterplot for the expression of miR.320a in HCs vs patients with MS. (E) Scatterplot for the expression of miR.27a.3p in patients with PMS vs RRMS. (F) Scatterplot for the expression of miR.27a.3p in patients with SPMS vs RRMS. AUC = area under the receiver operating characteristic curve; HC = healthy control; miRNA = microRNA; MS = multiple sclerosis; PMS = progressive multiple sclerosis; ROC = receiver operating characteristic; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis. Keren Regev et al. Neurol Neuroimmunol Neuroinflamm 2016;3:e267 © 2016 American Academy of Neurology

Download ppt "Figure 2. ROC curves for different group comparisons"

Similar presentations

Fig S1. miR-10b overexpression in exosomes derived from MDA-MB-231 cells stably expressing miR-10b as compared to vector control exosomes. Supplementary.

Fig S1. miR-10b overexpression in exosomes derived from MDA-MB-231 cells stably expressing miR-10b as compared to vector control exosomes. Supplementary.
Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)

Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)
Figure 3 Associations of [11C](R)-PK11195 binding to disability and diffusion tensor imaging (DTI) changes in patients with MS Associations of [11C](R)-PK11195.

Figure 3 Associations of [11C](R)-PK11195 binding to disability and diffusion tensor imaging (DTI) changes in patients with MS Associations of [11C](R)-PK11195.
Figure 2 Orbital MRI findings One-third of myelin oligodendrocyte glycoprotein antibody–positive patients revealed extensive enhancement patterns that.

Figure 2 Orbital MRI findings One-third of myelin oligodendrocyte glycoprotein antibody–positive patients revealed extensive enhancement patterns that.
Figure 3 Antibodies to MOG using different secondary antibodies: Anti-human IgG (H + L), IgG1, or IgM(A) Comparison of binding to full-length myelin oligodendrocyte.

Figure 3 Antibodies to MOG using different secondary antibodies: Anti-human IgG (H + L), IgG1, or IgM(A) Comparison of binding to full-length myelin oligodendrocyte.
Figure 3 Archetypal MS clinical course depicted over 20 years

Figure 3 Archetypal MS clinical course depicted over 20 years
Figure 2. Change in total PSPRS score from baseline to each study visit for all participants Change in total PSPRS score from baseline to each study visit.

Figure 2. Change in total PSPRS score from baseline to each study visit for all participants Change in total PSPRS score from baseline to each study visit.
Figure 4 Correlation of age with [11C](R)-PK11195 binding in the normal-appearing white matter (NAWM) and thalami Correlation of age with [11C](R)-PK11195.

Figure 4 Correlation of age with [11C](R)-PK11195 binding in the normal-appearing white matter (NAWM) and thalami Correlation of age with [11C](R)-PK11195.
Figure 5 Treatment with fingolimod raises the activation threshold of monocytes in MS Peripheral blood mononuclear cells from 8 healthy donors, 7 patients.

Figure 5 Treatment with fingolimod raises the activation threshold of monocytes in MS Peripheral blood mononuclear cells from 8 healthy donors, 7 patients.
Figure 3 JCV index changes in JCV+ patients

Figure 3 JCV index changes in JCV+ patients
Figure 1 Neuromyelitis optica spectrum disorder (NMOSD) subgroups and patients with relapsing-remitting multiple sclerosis (RRMS) show different antibody.

Figure 1 Neuromyelitis optica spectrum disorder (NMOSD) subgroups and patients with relapsing-remitting multiple sclerosis (RRMS) show different antibody.
Figure 1 Effect of DMF therapy on T cell subsets

Figure 1 Effect of DMF therapy on T cell subsets
Figure Nuclear Nrf2 expression after fumarate therapy A new left occipital fluid-attenuated inversion recovery hyperintense (A), T1 hypointense (B), and.

Figure Nuclear Nrf2 expression after fumarate therapy A new left occipital fluid-attenuated inversion recovery hyperintense (A), T1 hypointense (B), and.
Figure 4 Abundance of cytokines which showed significant difference in expression in the plasma and the cultured PBMC of patients with RRMS Abundance of.

Figure 4 Abundance of cytokines which showed significant difference in expression in the plasma and the cultured PBMC of patients with RRMS Abundance of.
Figure 2 Elevated antibody reactivities against myelin and Epstein-Barr virus (EBV) peptides in relapsing-remitting multiple sclerosis (RRMS) and higher.

Figure 2 Elevated antibody reactivities against myelin and Epstein-Barr virus (EBV) peptides in relapsing-remitting multiple sclerosis (RRMS) and higher.
Figure 2 Alemtuzumab-induced changes in the dendritic cell compartment

Figure 2 Alemtuzumab-induced changes in the dendritic cell compartment
Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.
Figure 1 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A)

Figure 1 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A)
Figure 1 Characteristics of the German National MS Cohort

Figure 1 Characteristics of the German National MS Cohort
Figure 1 Time points of blood sampling

Figure 1 Time points of blood sampling

Similar presentations

Ads by Google